Middle East Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 5/6
Middle East Pharmaceutical Industries has a total shareholder equity of SAR315.5M and total debt of SAR48.9M, which brings its debt-to-equity ratio to 15.5%. Its total assets and total liabilities are SAR455.8M and SAR140.3M respectively. Middle East Pharmaceutical Industries's EBIT is SAR87.4M making its interest coverage ratio 15.6. It has cash and short-term investments of SAR34.5M.
Key information
15.5%
Debt to equity ratio
ر.س48.86m
Debt
Interest coverage ratio | 15.6x |
Cash | ر.س34.53m |
Equity | ر.س315.50m |
Total liabilities | ر.س140.34m |
Total assets | ر.س455.84m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4016's short term assets (SAR284.9M) exceed its short term liabilities (SAR116.7M).
Long Term Liabilities: 4016's short term assets (SAR284.9M) exceed its long term liabilities (SAR23.7M).
Debt to Equity History and Analysis
Debt Level: 4016's net debt to equity ratio (4.5%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 4016's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 4016's debt is well covered by operating cash flow (213.1%).
Interest Coverage: 4016's interest payments on its debt are well covered by EBIT (15.6x coverage).